Teva Settles Opioid Litigation In Florida For $177m

Firm Will Also Provide State With $84m Worth Of Generic Narcan

Teva has settled the opioid claims it faced in the state of Florida, alongside CVS, Allergan and Endo.

Gavel resting inside book
Florida is the fifth jurisdiction Teva has settled with on opioid-related claims • Source: Alamy

Teva has made its second state-level opioid settlement in as many weeks, having reached an agreement with the attorney general of Florida that settles the claims of the state and its subdivisions against the pharmaceutical firm.

The company will pay the state $177m in staggered amounts over the next 15 years, as well as supplying $84m...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin